Rare disorder group says Orphan Drug Act "working as intended"

US patient advocacy group the National Organization for Rare Disorders (NORD) has published a new report into the Orphan Drug Act and related matters connected with the development and marketing of rare disease therapies.

The report, undertaken by industry analyst IQVIA, finds that the seven-year market exclusivity granted to drugs under the Orphan Drug Act is “working as intended.”

The NORD says that the granting of exclusivity has not “inappropriately prevent generics and biosimilars from entering the market.”